Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

Kyowa Hakko presents new phosphodiesterase inhibitors

June 7, 1999

Inflazyme initiates phase I clinical trials with IPL-576092

June 4, 1999

Dual TxA2 and PGD2 antagonists from Shionogi

June 4, 1999

New PDE4 inhibitors with reduced emetogenic potential in the Kyowa Hakko pipeline

June 3, 1999

Sepracor and UCB reach Zyrtec isomer licensing agreement

June 3, 1999

Cell Therapeutics terminates enrollment in lung injury trial of lisofylline

June 2, 1999

Aradigm and Genentech sign development agreement for cystic fibrosis therapy

June 2, 1999

PathoGenesis signs European distribution agreements and launches TOBI in two new markets

June 1, 1999

Improved PDE4 inhibitors in development at Merck Frosst

May 26, 1999

Muscarinic antagonists from Tokyo Tanabe particularly useful for respiratory disorders

May 25, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...